...
首页> 外文期刊>Drug Design, Development and Therapy >Integrated Network Pharmacology Analysis and Pharmacological Evaluation to Explore the Active Components and Mechanism of Abelmoschus manihot (L.) Medik. on Renal Fibrosis
【24h】

Integrated Network Pharmacology Analysis and Pharmacological Evaluation to Explore the Active Components and Mechanism of Abelmoschus manihot (L.) Medik. on Renal Fibrosis

机译:综合网络药理学分析及药理评估探讨Abelmoschus Manihot(L.)Medik的活性成分和机制。关于肾纤维化

获取原文
           

摘要

Background: Renal fibrosis is a common pathological outcome of chronic kidney diseases (CKD) that is considered as a global public health issue with high morbidity and mortality. The dry corolla of Abelmoschus manihot (L.) Medik. (AMC) has been used for chronic nephritis in clinic and showed a superior effect in alleviating proteinuria in CKD patients to losartan. However, the effective components and underlying mechanism of AMC in the treatment of renal fibrosis have not been systematically clarified. Methods: Based on drug-likeness evaluation, oral bioavailability prediction and compound contents, a systematic network pharmacology analysis was conducted to predict the active ingredients. Gene Ontology, Kyoto Encyclopedia of Genes and Genomes pathway analysis and protein–protein interaction analysis were applied to predict the potential pathway and target of AMC against renal fibrosis. The formula of component contribution index (CI) based on the algorithm was used to screen the principal active compounds of AMC in the treatment of renal fibrosis. Finally, pharmacological evaluation was conducted to validate the protective effect and primary predicted mechanism of AMC in the treatment of renal fibrosis on a 5/6 nephrectomy mice model. Results: Fourteen potential active components of AMC possessing favorable pharmacokinetic profiles and biological activities were selected and hit by 17 targets closely related to renal fibrosis. Quercetin, caffeic acid, 9.12-octadecadienoic acid, and myricetin are recognized as the more highly predictive components as their cumulative contribution rate reached 85.86%. The AMC administration on 5/6 nephrectomy mice showed a protective effect on kidney function and renal fibrosis. The hub genes analysis revealed that AMC plays a major role in inhibiting epithelial-to-mesenchymal transition during renal fibrosis. Conclusion: Our results predicted active components and potential targets of AMC for the application to renal fibrosis from a holistic perspective, as well as provided valuable direction for further research of AMC and improved comprehension of renal fibrosis pathogenesis.
机译:背景:肾纤维化是慢性肾病疾病(CKD)的常见病理结果,被认为是具有高发病率和死亡率的全球公共卫生问题。 Abelmoschus Manihot(L.)Medik的干燥花冠。 (AMC)已被用于诊所的慢性肾炎,并且在缓解CKD患者到氯沙坦的蛋白尿中表现出优异的效果。然而,没有系统澄清AMC治疗肾纤维化治疗的有效组分和潜在机制。方法:基于药物肖像评估,口服生物利用度预测和化合物含量,进行了系统网络药理学分析以预测活性成分。基因本体,京都基因和基因组途径分析和蛋白质 - 蛋白质相互作用分析的应用术语来预测AMC对肾纤维化的潜在途径和靶。基于该算法的组分贡献指数(CI)的配方用于筛选AMC的主要活性化合物,治疗肾纤维化。最后,进行了药理学评估,以验证AMC在5/6肾切除小鼠模型上治疗肾纤维化的保护作用和原发性预测机制。结果:选择具有良好的药代动力学曲线和生物活性的AMC潜在活性成分,并达到与肾纤维化密切相关的17个靶标。槲皮素,咖啡酸,9.12-十八二碳酸和霉菌素被认为是更高度预测的组件,因为它们的累积贡献率达到85.86%。 AMC给药对5/6肾切除术小鼠对肾功能和肾纤维化的保护作用。枢纽基因分析显示,AMC在抑制肾纤维化期间抑制上皮性与间充质转换的主要作用。结论:我们的结果预计从整体角度施用肾纤维化的AMC的活性成分和潜在目标,以及为进一步研究AMC和改善肾纤维化发病机制的改善理解提供了有价值的方向。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号